Exploring the Relationship between FEV1 Loss and Recovery and Aminoglycoside Pharmacokinetics in Adult Patients with Cystic Fibrosis: Implications for Clinical Dosing Strategies.

Brian M HoffMarc H ScheetzManu JainJoanne F CullinaNathaniel James Rhodes

Published in: Pharmacotherapy (2020)

Increasing aminoglycoside AUC0-24 hr and Cmax0-24 hr were not associated with FEV1 during PEx treatment. Although individualizing aminoglycoside dosing in adult CF patients is necessary to minimize toxicity risk, more work is needed to define optimally safe and effective dosing strategies for this population.

Keyphrases

pseudomonas aeruginosa
end stage renal disease
acinetobacter baumannii
ejection fraction
newly diagnosed
cystic fibrosis
chronic kidney disease
oxidative stress
patient reported outcomes
replacement therapy